BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38695144)

  • 1. Outcomes and genetic dynamics of acute myeloid leukemia at first relapse.
    Bataller A; Kantarjian H; Bazinet A; Kadia T; Daver N; DiNardo CD; Borthakur G; Loghavi S; Patel K; Tang G; Sasaki K; Short NJ; Yilmaz M; Issa GC; Alvarado Y; Montalban-Bravo G; Maiti A; Abbas HA; Takahashi K; Pierce S; Jabbour E; Garcia-Manero G; Ravandi F
    Haematologica; 2024 May; ():. PubMed ID: 38695144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved outcome in AML relapse after allogeneic transplant with high-intensity chemotherapy followed by 2nd allogeneic stem cell transplant or donor lymphocyte infusion.
    Shah N; Rakszawski K; Nickolich M; Ehmann C; Wirk B; Naik S; Rybka W; Zheng H; Mierski J; Silar B; Mackey G; Greiner R; Brown V; Claxton D; Mineishi S; Minagawa K
    Ann Hematol; 2021 Oct; 100(10):2585-2592. PubMed ID: 34322774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytogenetic risk grouping by the monosomal karyotype classification is superior in predicting the outcome of acute myeloid leukemia undergoing allogeneic stem cell transplantation in complete remission.
    Hemmati PG; Schulze-Luckow A; Terwey TH; le Coutre P; Vuong LG; Dörken B; Arnold R
    Eur J Haematol; 2014 Feb; 92(2):102-10. PubMed ID: 24138573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
    Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
    Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of TP53 mutations over the course of therapy for acute myeloid leukemia.
    Alwash Y; Khoury JD; Tashakori M; Kanagal-Shamanna R; Daver N; Ravandi F; Kadia TM; Konopleva M; Dinardo CD; Issa GC; Loghavi S; Takahashi K; Jabbour E; Guerra V; Kornblau S; Kantarjian H; Short NJ
    Am J Hematol; 2021 Nov; 96(11):1420-1428. PubMed ID: 34351647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of Intermediate Risk Karyotype Acute Myeloid Leukemia in First Remission Undergoing Autologous Stem Cell Transplantation Compared With Allogeneic Stem Cell Transplantation and Chemotherapy Consolidation: A Retrospective, Propensity-score Adjusted Analysis.
    Limvorapitak W; Barnett MJ; Hogge DE; Forrest DL; Nevill TJ; Narayanan S; Power MM; Nantel SH; Broady R; Song KW; Toze CL; Mourad YA; Sutherland HJ; Gerrie AS; White J; Sanford DS
    Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e481-e491. PubMed ID: 30100330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients With Acute Myeloid Leukemia Harboring
    Jiang B; Zhao Y; Luo Y; Yu J; Chen Y; Ye B; Fu H; Lai X; Liu L; Ye Y; Zheng W; Sun J; He J; Zhao Y; Wei G; Cai Z; Huang H; Shi J
    Cell Transplant; 2024; 33():9636897231225821. PubMed ID: 38270130
    [No Abstract]   [Full Text] [Related]  

  • 8. Chemotherapy or Allogeneic Stem Cell Transplantation as Salvage Therapy for Patients with Refractory Acute Myeloid Leukemia: A Multicenter Analysis.
    Wang ZY; Gao WH; Zhao HJ; Yin CR; Wang ZW; Tian L; Wang L; Wang LN; Jiang JL; Devillier R; Wan M; Wang JM; Huang PP; Blaise D; Hu J
    Acta Haematol; 2022; 145(4):419-429. PubMed ID: 35231903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation.
    Bazinet A; Kantarjian H; Arani N; Popat U; Bataller A; Sasaki K; DiNardo CD; Daver N; Yilmaz M; Abbas HA; Short NJ; Issa G; Jabbour E; Pierce SA; Chen J; Garcia R; Konopleva M; Garcia-Manero G; Alousi A; Shpall EJ; Champlin RE; Borthakur G; Ravandi F; Kadia T
    Am J Hematol; 2023 Sep; 98(9):1383-1393. PubMed ID: 37334870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment responses, outcomes, and prognostic factors associated with them in patients with secondary acute myeloid leukemia].
    Ma L; Zhao T; Chen YY; Jiang H; Xu LP; Zhang XH; Wang Y; Sun YQ; Mo XD; Huang XJ; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2023 Feb; 44(2):124-131. PubMed ID: 36948866
    [No Abstract]   [Full Text] [Related]  

  • 11. [Efficacy and safety of IAC regimen for relapse/refractory acute myeloid leukemia: a prospective randomized controlled study].
    Li CH; Wei SN; Qiu SW; Gong BF; Gong XY; Li Y; Liu YT; Fang QY; Zhang GJ; Liu KQ; Zhou CL; Lin D; Liu BC; Wang Y; Mi YC; Wei H; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2022 Apr; 43(4):287-292. PubMed ID: 35680626
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia.
    Fleischmann M; Scholl S; Frietsch JJ; Hilgendorf I; Schrenk K; Hammersen J; Prims F; Thiede C; Hochhaus A; Schnetzke U
    J Cancer Res Clin Oncol; 2022 Nov; 148(11):3191-3202. PubMed ID: 35099591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Allo-HSCT for acute myeloid leukemia with myelodysplastic-related changes: a clinical analysis].
    Zhang HX; Pang AM; Chen X; Zhang RL; Zhai WH; Ma QL; Yang DL; Wei JL; He Y; Feng SZ; Han MZ; Jiang EL
    Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):814-822. PubMed ID: 34788920
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy and safety of venetoclax plus hypomethylating agents in relapsed/refractory acute myeloid leukemia: a multicenter real-life experience.
    Angotzi F; Lessi F; Leoncin M; Filì C; Endri M; Lico A; Visentin A; Pravato S; Candoni A; Trentin L; Gurrieri C
    Front Oncol; 2024; 14():1370405. PubMed ID: 38680863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relapse and survival after transplantation for complex karyotype acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and the University of Texas MD Anderson Cancer Center.
    Ciurea SO; Labopin M; Socie G; Volin L; Passweg J; Chevallier P; Beelen D; Milpied N; Blaise D; Cornelissen JJ; Fegueux N; Polge E; Kongtim P; Rondon G; Esteve J; Mohty M; Savani BN; Champlin RE; Nagler A
    Cancer; 2018 May; 124(10):2134-2141. PubMed ID: 29469961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Cytogenetic Risk on Outcomes of Non-T-Cell-Depleted Haploidentical Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia.
    Nagler A; Labopin M; Dholaria B; Ciceri F; Fraccaroli A; Blaise D; Fanin R; Bruno B; Forcade E; Vydra J; Chevallier P; Bulabois CE; Jindra P; Bornhäuser M; Canaani J; Sanz J; Savani BN; Spyridonidis A; Giebel S; Brissot E; Bazarbachi A; Esteve J; Mohty M
    Transplant Cell Ther; 2022 Nov; 28(11):773.e1-773.e8. PubMed ID: 36031079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of a Second Allogeneic Hematopoietic Cell Transplant in Relapsed Acute Myeloid Leukemia: Results of a Systematic Review and Meta-Analysis.
    Kharfan-Dabaja MA; Reljic T; Yassine F; Nishihori T; Kumar A; Tawk MM; Keller K; Ayala E; Savani B; Mohty M; Aljurf M; Saber W
    Transplant Cell Ther; 2022 Nov; 28(11):767.e1-767.e11. PubMed ID: 35970301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome for children treated for relapsed or refractory acute myelogenous leukemia (rAML): a Therapeutic Advances in Childhood Leukemia (TACL) Consortium study.
    Gorman MF; Ji L; Ko RH; Barnette P; Bostrom B; Hutchinson R; Raetz E; Seibel NL; Twist CJ; Eckroth E; Sposto R; Gaynon PS; Loh ML
    Pediatr Blood Cancer; 2010 Sep; 55(3):421-9. PubMed ID: 20658611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
    Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
    Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure.
    Short NJ; Venugopal S; Qiao W; Kadia TM; Ravandi F; Macaron W; Dinardo CD; Daver N; Konopleva M; Borthakur G; Shpall EJ; Popat U; Champlin RE; Mehta R; Al-Atrash G; Oran B; Jabbour E; Garcia-Manero G; Issa GC; Montalban-Bravo G; Yilmaz M; Maiti A; Kantarjian H
    J Hematol Oncol; 2022 Jan; 15(1):12. PubMed ID: 35093134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.